This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll more

Esperoct® offers patients with haemophilia A a treatment tailored to their needs with higher FVIII activity levels and low ABR allowing them to move beyond the conventional limitations of haemophilia A1-4.

Over 30 years of research and clinical experience NovoSeven® supporting your patients in more indications than any other bypassing agent.
New! NovoSeven® for severe postpartum hemorrhage when uterotonics are not sufficient to stop the bleed5-9.

Refixia® is an extended half-life recombinant FIX used in routine prophylaxis as well as for bleed control and surgical procedure for HB patients10. Refixia® once weekly prophylaxis gives your patient the confidence to live beyond haemophilia B maintaining high FIX activity level in the non-haemophilia range most of the time10-14.

With Changing Haemophilia® we address the unmet needs in haemophilia and other rare blood disorders. Together with you and our community partners we are striving for better access to care, diagnosis and multidisciplinary care.

The lack of awareness of rare diseases and treatment options can make the entire experience, from diagnosis onwards, one of challenges and uncertainty. The complexities and challenges of diagnosing and managing each rare disease overlap greatly with many shared commonalities, and do not vary as much as the diseases themselves.


Esperoct® Summary of Product Characteristics, 2020.


Chowdary P et al. Res Pract Thromb Haemost 2019; 3:542–554.


Giangrande P et al. J Thromb Haemost 2017; 117:252–261.


Giangrande P et al. J Thromb Haemost 2020; 18:5–14


NovoSeven® Summary of Product Characteristics, accessed: Jan 2023.


Hedner, 2015, Blood Reviews


FEIBA 500 U Summary of Product Characteristics, Jan 2016


Obizur EMA Summary of Product Characteristics, April 2022


Hemlibra Summary of Product Characteristics, Sep 2022


Refixia® Summary of Product Characteristics, 2022.


Collins PW et al. Blood 2014; 124:3880–3886.


Negrier C et al. Haemophilia 2016; 22:507–513.


Tiede A et al. Haemophilia 2017; 23:547–555.


Young G et al. Thromb Res 2016; 141:69–76.